Docetaxel–trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

BACKGROUND: Trastuzumab plus docetaxel is a mainstay to treat HER2-positive breast cancers. However, developing nanoparticles could help to improve the efficacy/toxicity balance of this doublet by improving drug trafficking and delivery to tumors. This project aimed to develop an immunoliposome in b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodallec, Anne, Brunel, Jean-Michel, Giacometti, Sarah, Maccario, Helene, Correard, Florian, Mas, Eric, Orneto, Caroline, Savina, Ariel, Bouquet, Fanny, Lacarelle, Bruno, Ciccolini, Joseph, Fanciullino, Raphaelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014390/
https://www.ncbi.nlm.nih.gov/pubmed/29950829
http://dx.doi.org/10.2147/IJN.S162454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014390/
https://www.ncbi.nlm.nih.gov/pubmed/29950829
http://dx.doi.org/10.2147/IJN.S162454

Ejemplares similares